Baricitinib vs methotrexate for skin tightening in scleroderma
Part of Skin clinical trials.
This study tests if baricitinib (a daily pill) is better than methotrexate (a common treatment) at reducing skin tightening in people with a severe type of scleroderma called diffuse cutaneous systemic sclerosis. It may help if your skin is getting tighter and you have been diagnosed in the last 5 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse cutaneous systemic sclerosis (scleroderma that affects large areas of skin).
- Your first non-Raynaud symptom (like skin swelling or pain) started within the last 5 years.
- Your skin tightness score is at least 10 out of 51, measured by a doctor's exam.
- You are not on certain other medications like high doses of steroids or mycophenolate mofetil.
- You do not have serious infections, active tuberculosis, hepatitis B or C, or certain lab test abnormalities.
- If you could become pregnant, you must use effective birth control during the study and for 28 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.